CANCER AND LEUKEMIA GROUP B--RPCI/SUNYAB

癌症和白血病 B 组--RPCI/SUNYAB

• 批准号: 3559039
• 负责人: ELLIS G LEVINE
• 金额: $ 21.77万
• 依托单位: ROSWELL PARK CANCER INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-04-15 至 1998-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3559039
• 关键词: B lymphocyte; Hodgkin's disease; acute leukemia; acute myelogenous leukemia; acute nonlymphocytic leukemia; alkylating agents; antineoplastics; autologous transplantation; azacitidine; bladder neoplasm; bone marrow transplantation; breast neoplasms; cancer registry /resource; carmustine; chromosome translocation; chronic myelogenous leukemia; cis platinum compound; clinical trials; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cystectomy; cytosine arabinoside; daunorubicin; deoxycoformycin; doxorubicin; drug design /synthesis /production; drug resistance; esophagus neoplasm; etoposide; flow cytometry; fluorouracil; gastrointestinal neoplasms; gene rearrangement; hairy cell leukemia; human subject; human therapy evaluation; ifosfamide; immunoglobulin genes; interferon alpha; interferon gamma; interleukin 2; interleukin 3; leucovorin; liposomes; lung neoplasms; lymphocytic leukemia; lymphoma; melphalan; mesothelioma; mitomycins; mitoxantrone; monoclonal antibody; multiple myeloma; myelogenous leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer remission /regression; neoplasm /cancer surgery; nonHodgkin's lymphoma; osteosarcoma; polymerase chain reaction; prednisone; prostate neoplasms; protooncogene; somatostatin; splenectomy; transitional cell carcinoma; trisomy

Roswell Park Cancer Institute (RPCI) is requesting support to continue its participation in Cancer and Leukemia Group B (CALGB). For the past 3 years, since the arrival of Dr. Bloomfield, interim funding has been secured to allow RPCI to develop its present role in the Group. The goals of the CALGB participation include: (i) increased accrual to phase II/phase III clinical trials, based upon a steadily increasing patient recruitment since the reorganization of clinical services at RPCI; a particular emphasis will be placed upon solid tumor oncology and new drug development; (ii) increased investigator participation in CALGB activities, consequent upon a major program of recruitment; (iii) increased scientific contribution, based upon the application of selected aspects of our rapidly evolving translational research program to CALGB; (iv) increased attention to minority groups with the development of specific multimodality clinics for patients with esophagus and prostate cancer. Founded in 1898, Roswell Park Cancer Institute (RPCI) was one of the first institutions dedicated exclusively to the research and treatment of cancer and allied diseases. With more than 1400 staff, 200 beds, a large outpatient facility, and nearly 1,000,000 square feet of laboratory and hospital space provided by the State of New York, RPCI constitutes one of the 3 largest Cancer Centers in the United States, and was one of the first NCI-designated Comprehensive Cancer Centers. Under the direction of a team of senior investigators with major track records in clinical trial design and methodology and multidisciplinary management, the staff at RPCI and affiliates have increased accrual to CALGB trials from only 31 cases in 1988 to 162 in 1991, with a projected accrual of 200 in 1992. Increasing accrual has been seen at both the Main institution and at the affiliates, with a particular increase recently in solid tumor recruitment. RPCI also contributes substantially to the scientific, administrative, core, and publication activities of CALGB, as evidenced by the 60 protocols currently or recently chaired by staff members; the presence of the Offices of the Correlative Science, Cytogenetics and Pathology Committees and Flow Cytometry Core Facilities; active participation in Core Committees; authorship on 84 CALGB publications since 1988; and the completion of many early phase/pilot studies that have given rise to subsequent CALGB protocols. With the development of a new marrow transplant program and a new commitment to multidisciplinary management of solid tumors (augmented by a further increase in the intramural level of translational research, e.g., the current development of an extensive program of interactive laboratory research between the Departments of Medicine, Surgery, Flow Cytometry, Pathology and the Grace Cancer Drug Center targeted on mechanisms of response and resistance to treatment), a new level of scientific leadership will be available to CALGB as Roswell Park Cancer Institute completes its first century of cancer research.

罗斯威尔公园癌症研究所（RPCI）要求支持继续 它参与癌症和白血病B组（CALGB）。 过去 3年以来，自布鲁姆菲尔德博士到来以来，临时资金一直是 有担保允许RPCI在该小组中发展其目前的作用。 这 CALB参与的目标包括：（i）增加应计 II阶段/III期临床试验，基于稳定增长 自临床服务重组以来的患者招募 rpci;特别重点将放在实体肿瘤学上 和新药物开发； （ii）增加研究者参与 小牛活动，构成重大招聘计划； （iii） 根据应用的应用 我们快速发展的转化研究计划的选定方面 到Calgb； （iv）增加对少数群体的关注 为患者开发特定的多模式诊所 食道和前列腺癌。 罗斯威尔公园癌于1898年成立 研究所（RPCI）是专门的第一批机构之一 专门从事癌症和盟友的研究和治疗 疾病。 拥有1400多名员工，200张床，大门诊 设施，近100万平方英尺的实验室和医院 纽约州提供的空间，RPCI构成了其中一个 美国3个最大的癌症中心，是第一个 NCI指定的综合癌症中心。 在指导下 一个高级调查员的团队，具有临床上的主要记录 试验设计和方法论以及多学科管理， RPCI和分支机构的工作人员增加了Calgb试验的应计 从1988年的31例案件到1991年的162个案件，预计应计 1992年200。 机构和分支机构，最近有特殊的增长 在实体肿瘤中。 RPCI也为 Calgb的科学，行政，核心和出版活动， 正如目前或最近由员工主持的60个协议所证明的 成员；相关科学办公室的存在， 细胞遗传学和病理委员会以及流式细胞仪核心 设施;积极参加核心委员会； 84的作者身份 自1988年以来的Calgb出版物；以及许多早期的完成 引起随后的CALGB方案的相/初步研究。 随着新的骨髓移植程序的制定和新的 对实体瘤的多学科管理的承诺（增强 通过进一步提高壁内翻译水平 研究，例如，当前的广泛计划的发展 医学部门之间的互动实验室研究， 手术，流式细胞术，病理学和宽限期癌症药物中心 针对反应机制和对治疗的抵抗力），一种新的 科学领导水平将作为罗斯威尔（Roswell）提供的科学领导力 公园癌研究所完成了其第一世纪的癌症研究。